Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BSTCNASDAQ:BYSINASDAQ:MRUSNASDAQ:STSANASDAQ:SYRS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSTCBioSpecifics Technologies$88.53$88.47$42.00▼$89.15$650.25M0.2461,105 shsN/ABYSIBeyondSpring$2.27-6.6%$2.41$0.65▼$4.00$88.36M0.15185,227 shs28,389 shsMRUSMerus$44.93+7.1%$45.03$18.21▼$52.03$2.64B1.1592,308 shs1.92 million shsSTSASatsuma Pharmaceuticals$1.10-0.9%$1.08$0.59▼$8.08$36.47M0.1701,788 shs1.83 million shsSYRSSyros Pharmaceuticals$5.10+0.6%$6.09$2.09▼$8.17$136.32M1.74213,763 shs128,568 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSTCBioSpecifics Technologies0.00%0.00%0.00%0.00%0.00%BYSIBeyondSpring-6.58%+26.11%-37.12%+149.40%+134.36%MRUSMerus+7.05%+11.02%+0.04%+31.99%+126.80%STSASatsuma Pharmaceuticals0.00%0.00%0.00%0.00%+4.75%SYRSSyros Pharmaceuticals+0.59%+8.05%-18.40%-25.76%+61.90%These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ABYSIBeyondSpring0.0016 of 5 stars0.00.00.00.00.02.50.0MRUSMerus2.4649 of 5 stars4.52.00.00.01.81.70.0STSASatsuma PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASYRSSyros Pharmaceuticals3.8525 of 5 stars3.51.00.04.31.13.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSTCBioSpecifics TechnologiesN/AN/AN/AN/ABYSIBeyondSpringN/AN/A$1.25-44.93% DownsideMRUSMerus3.00Buy$56.3325.38% UpsideSTSASatsuma PharmaceuticalsN/AN/AN/AN/ASYRSSyros Pharmaceuticals3.00Buy$14.33181.05% UpsideCurrent Analyst RatingsLatest BSTC, STSA, SYRS, MRUS, and BYSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/11/2024MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.004/3/2024SYRSSyros PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$13.004/1/2024SYRSSyros PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.003/28/2024MRUSMerusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$69.003/4/2024MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$42.00 ➝ $65.002/29/2024MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$48.00 ➝ $65.002/29/2024MRUSMerusStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $65.002/29/2024MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$49.00 ➝ $58.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSTCBioSpecifics Technologies$38.19M17.03$3.38 per share26.18$18.42 per share4.81BYSIBeyondSpring$1.55M57.00N/AN/A($0.36) per share-6.31MRUSMerus$43.95M60.00N/AN/A$6.17 per share7.28STSASatsuma PharmaceuticalsN/AN/AN/AN/A$1.41 per shareN/ASYRSSyros Pharmaceuticals$9.94M13.71N/AN/A$0.79 per share6.46Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSTCBioSpecifics Technologies$24.47M$3.3337.5117.60N/A47.43%14.81%14.46%N/ABYSIBeyondSpring-$33.28MN/A0.00∞N/AN/AN/AN/AN/AMRUSMerus-$154.94M-$3.04N/AN/AN/A-352.56%-50.61%-37.56%5/2/2024 (Estimated)STSASatsuma Pharmaceuticals-$70.06M-$2.01N/AN/AN/AN/A-115.24%-102.26%N/ASYRSSyros Pharmaceuticals-$164.57M-$5.76N/AN/AN/A-1,656.34%-227.91%-75.60%5/8/2024 (Estimated)Latest BSTC, STSA, SYRS, MRUS, and BYSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023SYRSSyros Pharmaceuticals-$1.23-$1.19+$0.04-$0.20$2.40 million$0.39 million2/28/2024Q4 2023MRUSMerus-$0.71-$1.09-$0.38-$1.09$10.43 million$8.94 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ASTSASatsuma PharmaceuticalsN/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSTCBioSpecifics TechnologiesN/A66.2466.24BYSIBeyondSpringN/AN/AN/AMRUSMerusN/A5.345.34STSASatsuma PharmaceuticalsN/A7.447.44SYRSSyros Pharmaceuticals2.073.953.95OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSTCBioSpecifics Technologies60.34%BYSIBeyondSpring40.29%MRUSMerus96.14%STSASatsuma Pharmaceuticals93.26%SYRSSyros Pharmaceuticals91.47%Insider OwnershipCompanyInsider OwnershipBSTCBioSpecifics Technologies15.70%BYSIBeyondSpring29.31%MRUSMerus4.30%STSASatsuma Pharmaceuticals31.20%SYRSSyros Pharmaceuticals10.45%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBSTCBioSpecifics Technologies77.35 millionN/ANot OptionableBYSIBeyondSpring7338.92 million27.52 millionOptionableMRUSMerus17258.69 million56.16 millionOptionableSTSASatsuma Pharmaceuticals2133.15 million22.81 millionNot OptionableSYRSSyros Pharmaceuticals6826.73 million23.94 millionOptionableBSTC, STSA, SYRS, MRUS, and BYSI HeadlinesSourceHeadlineSyros Pharmaceuticals (NASDAQ:SYRS) Downgraded to Sell at StockNews.comamericanbankingnews.com - April 18 at 5:56 AMSyros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.commarketbeat.com - April 17 at 11:13 PMSyros Pharmaceuticals (NASDAQ:SYRS) Stock Passes Below 50-Day Moving Average of $6.38americanbankingnews.com - April 17 at 5:08 AMSyros Pharmaceuticals Shares Rise 20% on FDA Fast-Track Designation for Tamibarotenemarketwatch.com - April 10 at 5:56 PMSyros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AMLzacks.com - April 10 at 10:50 AMSyros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?zacks.com - April 10 at 9:31 AMSyros jumps on FDA fast track tag for leukemia drugmsn.com - April 9 at 3:57 PMFast Track Designation For Syros' Tamibarotene To Treat Acute Myeloid Leukemiamarkets.businessinsider.com - April 9 at 10:45 AMSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionbusinesswire.com - April 9 at 7:00 AMSyros Pharmaceuticals (NASDAQ:SYRS) Receives Overweight Rating from Piper Sandlermarketbeat.com - April 3 at 12:14 PMSyros Pharmaceuticals, Inc. Expected to Earn Q1 2024 Earnings of ($1.20) Per Share (NASDAQ:SYRS)marketbeat.com - April 3 at 6:00 AMSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - April 2 at 4:30 PMSyros Pharmaceuticals (NASDAQ:SYRS) Receives "Buy" Rating from HC Wainwrightmarketbeat.com - April 1 at 8:22 AMSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Up 31.8% in Marchmarketbeat.com - March 30 at 12:39 PMSyros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 29 at 11:42 PMEarnings call: Syros Pharmaceuticals strong Q4 and full year financialsinvesting.com - March 29 at 11:42 PMSyros Pharmaceuticals, Inc. to Post Q1 2024 Earnings of ($0.74) Per Share, Brookline Capital Management Forecasts (NASDAQ:SYRS)marketbeat.com - March 29 at 8:15 AMSyros Pharmaceuticals (NASDAQ:SYRS) Upgraded to Hold by StockNews.commarketbeat.com - March 28 at 11:15 PMSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 28 at 12:38 PMAnalysts Issue Forecasts for Syros Pharmaceuticals, Inc.'s FY2028 Earnings (NASDAQ:SYRS)marketbeat.com - March 28 at 8:59 AMSyros Pharmaceuticals: Buy Rating on Strong Financials and High Potential of Tamibarotene Trialsmarkets.businessinsider.com - March 28 at 7:37 AMSyros Pharmaceuticals Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - March 28 at 7:37 AMSyros Pharmaceuticals earnings preview: what Wall Street is expectingmarkets.businessinsider.com - March 27 at 4:30 PMSYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 27 at 12:05 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBioSpecifics TechnologiesNASDAQ:BSTCBioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.BeyondSpringNASDAQ:BYSIBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.MerusNASDAQ:MRUSMerus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Satsuma PharmaceuticalsNASDAQ:STSASatsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Syros PharmaceuticalsNASDAQ:SYRSSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.